NCT03525834View on ClinicalTrials.gov

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

September 25, 2020

Study Completion Date

September 25, 2020

Conditions
Renal Angiomyolipoma
Interventions
DRUG

Everolimus

Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.

Trial Locations (5)

100028

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

200032

Novartis Investigative Site, Shanghai

430030

Novartis Investigative Site, Wuhan

610041

Novartis Investigative Site, Chengdu

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY